Cord immunoproteins as predictors of respiratory outcome in preterm infants

被引:43
作者
Kaukola, Tuula [1 ]
Tuimala, Jarno [3 ]
Herva, Riitta [2 ]
Kingsmore, Stephen [4 ]
Hallman, Mikko [1 ]
机构
[1] Univ Oulu, Dept Pediat, Fac Med, SF-90100 Oulu, Finland
[2] Univ Oulu, Dept Pathol, Fac Med, SF-90100 Oulu, Finland
[3] Finnish IT Ctr Sci, Espoo, Finland
[4] Natl Ctr Genome Resources, Santa Fe, NM USA
关键词
bronchopulmonary dysplasia; cytokines; immunoproteins in cord blood; preterm birth; respiratory distress syndrome; FETAL INFLAMMATORY RESPONSE; CHRONIC LUNG-DISEASE; BRONCHOPULMONARY DYSPLASIA; INTRAAMNIOTIC ENDOTOXIN; SURFACTANT; CHORIOAMNIONITIS; INTERLEUKIN-6; CYTOKINES; MATRIX-METALLOPROTEINASE-9; EXPRESSION;
D O I
10.1016/j.ajog.2008.07.070
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: The purpose of this study was to evaluate the role of cord blood proteins and antenatal factors in the prediction of respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD). STUDY DESIGN: The prospectively collected cohort included 163 infants. All infants were born between 1998-2002 in a single regional hospital before 32 weeks of gestation and survived the first hospitalization. Altogether, 107 cord blood proteins were analyzed. Twenty-two antenatal clinical factors were included in the data mining and logistic regression analyses. RESULTS: The incidence of RDS was 64% and of BPD was 25%. Histologic chorioamnionitis protected from RDS (odds ratio [OR], 0.24; 95% confidence interval [CI], 0.11-0.53; P < .001). Besides the length of gestation, other clinical factors poorly predicted the outcomes. Matrix metalloproteinase-9 independently predicted RDS (OR, 8.3; 95% CI, 3.0-23.1; P < .001). Soluble glycoprotein 130 independently predicted BPD (OR, 6.07; 95% CI, 2.20-16.7; P < .001). CONCLUSION: Specific antenatal immunologic activation predicts either acute or chronic respiratory disease in very preterm infants.
引用
收藏
页码:100.e1 / 100.e8
页数:8
相关论文
共 41 条
[1]  
BENIRSCHKE K, 2000, PATHOLOGY HUMAN PLAC, P16
[2]   The role of TARC in the pathogenesis of allergic asthma [J].
Berin, MC .
DRUG NEWS & PERSPECTIVES, 2002, 15 (01) :10-16
[3]   Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth [J].
Bry, K ;
Lappalainen, U ;
Hallman, M .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12) :2992-2999
[4]   Cytokine-induced cell death in human oligodendroglial cell lines.: II:: Alterations in gene expression induced by interferon-γ and tumor necrosis factor-α [J].
Buntinx, M ;
Gielen, E ;
Van Hummelen, P ;
Raus, J ;
Ameloot, M ;
Steels, P ;
Stinissen, P .
JOURNAL OF NEUROSCIENCE RESEARCH, 2004, 76 (06) :846-861
[5]   Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures [J].
Conroy, SM ;
Nguyen, V ;
Quina, LA ;
Blakely-Gonzales, P ;
Ur, C ;
Netzeband, JG ;
Prieto, AL ;
Gruol, DL .
JOURNAL OF NEUROIMMUNOLOGY, 2004, 155 (1-2) :43-54
[6]   Outcome of neonates less than 30 weeks gestation with histologic chorioamnionitis [J].
Dempsey, E ;
Chen, MF ;
Kokottis, T ;
Vallerand, D ;
Usher, R .
AMERICAN JOURNAL OF PERINATOLOGY, 2005, 22 (03) :155-159
[7]   Early increased levels of matrix metalloproteinase-9 in neonates recovering from respiratory distress syndrome [J].
Dik, WA ;
van Kaam, AHLC ;
Dekker, T ;
Naber, BAE ;
Janssen, DJ ;
Kroon, AA ;
Zimmermann, LJI ;
Versnel, MA ;
Lutter, R .
BIOLOGY OF THE NEONATE, 2006, 89 (01) :6-14
[8]   Historical insights into cytokines [J].
Dinarello, Charles A. .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 :S34-S45
[9]   Cluster analysis and display of genome-wide expression patterns [J].
Eisen, MB ;
Spellman, PT ;
Brown, PO ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14863-14868
[10]   Degree of lung maturity determines the direction of the interleukin-1-induced effect on the expression of surfactant proteins [J].
Glumoff, V ;
Väyrynen, O ;
Kangas, T ;
Hallman, M .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (03) :280-288